key: cord-0802557-r0wbv5xr authors: Pierre, O; Riveros, C; Charpy, S; Boutron, I title: Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19. date: 2021-09-20 journal: J Clin Epidemiol DOI: 10.1016/j.jclinepi.2021.09.022 sha: 5f2f3d5e262db415426b48600885bb027815b8a7 doc_id: 802557 cord_uid: r0wbv5xr OBJECTIVES: : To assess the sensitivity of two secondary electronic sources of COVID-19 studies: 1) the Cochrane COVID-19 Study Register (https://covid-19.cochrane.org/); and, 2) the Living Overview of the Evidence (L•OVE) COVID-19 platform (https://iloveevidence.com/). STUDY DESIGN AND SETTING: : We identified reports of randomized controlled trials (RCTs) and observational studies (OS) assessing preventive interventions or treatment for COVID-19. The reference standard comprised all reports included in the COVID-NMA platform (covid-nma.com), in two major living systematic reviews of RCTs assessing pharmacologic treatment of COVID-19, or identified in either of the two secondary sources evaluated. The search for all sources was conducted through September 7, 2020. Our primary outcome was the proportion of the reports included in the reference standard that were identified by each secondary source. RESULTS: : We identified 680 reports, 91 RCT reports, 97 RCT protocols, and 492 OS reports. The Cochrane COVID-19 Study Register identified 88% [95% confidence interval, 79-94] of the RCT reports, 90% [82-95] of the RCT protocols, and 82% [78-85] of the OS reports. The L•OVE platform identified 100% [97-100] of the RCT reports and RCT protocols and 100% [99-100] of the OS reports. CONCLUSION: : These platforms proved to be a viable screening alternative to searching every individual source. In December 2019, the first reports documented a novel coronavirus outbreak in Wuhan, Hubei Province, China. This novel coronavirus, known as SARS-CoV-2, spread from China to several countries and then around the world; the declared COVID-19, the illness caused by the virus, to be a pandemic on March 11, 2020. 1 Since then, there has been an explosion of research globally seeking to combat this major public health threat by evaluating the effectiveness and safety of various interventions aimed at preventing or treating COVID-19. Under these circumstances, the rapid production of high-quality, comprehensive, up-to-date living systematic reviews is indispensable to facilitate evidence-based decision making. One example includes the COVID-NMA initiative, which identifies, extracts, and synthesizes all randomized controlled trials (RCTs) evaluating the prevention and/or treatment of COVID-19. 2 All results are made available and updated weekly on the COVID-NMA platform (covidnma.com). However, performing and promptly updating a high-quality living systematic review is very labor intensive. A complex strategy that screens a large number of records is usually needed to accurately and comprehensively identify all eligible reports. To ensure the sustainability of living systematic reviews, it is essential to explore new approaches to study identification. [3] [4] [5] In the context of the COVID-19, some organizations have developed secondary electronic sources that systematic reviewers can use to identify eligible studies for their living reviews. In particular, the Cochrane COVID-19 study register 6 (https://covid-19.cochrane.org/) and the Living Overview of the Evidence (L·OVE) COVID-19 platform, 7 developed by the Epistemonikos Foundation (https://app.iloveevidence.com/covid19), offer free access to their up-to-date databases of COVID-19 studies, screened and annotated by PICO and study design. Searches on these platforms are facilitated through filters and data can be easily downloaded. Consequently, we decided to explore the sensitivity of these sources to determine if they could serve as a principal or even unique source for the search strategy of living systematic reviews of interventional studies for COVID-19. The objective of this study was to evaluate the sensitivity of two secondary sources (the Cochrane COVID-19 study register and the L·OVE COVID-19 platform) for the identification of publications in preprint or peer-reviewed journal of 1) RCTs, 2) RCT protocols, and 3) OS assessing interventions to prevent or treat COVID-19. We conducted a cross-sectional study, embedded within the COVID-NMA initiative. 2 We included RCT reports and protocols (i.e., preprint or publication in a journal of the protocol) and OS that assessed: 1) Interventions to prevent the spread of SARS-CoV-2 infection (e.g., vaccine, prophylactic pharmacologic treatments, and nonpharmacologic interventions for preventing SARS-CoV-2 transmission, such as personal protective equipment) 2) Interventions for treating COVID-19 (e.g., anti-infective agents, specific and nonspecific immunomodulators, supportive treatments for hospitalized patients, and general treatments for viral infection) Prognostic studies, systematic reviews, meta-analyses, post-hoc analyses, and diagnostic test sensitivity studies were excluded, as were reports of studies evaluating traditional Chinese medicine or other herbal therapies. The Cochrane COVID-19 Study Register The Cochrane COVID-19 Study Register was funded by Cochrane to support rapid evidence synthesis. This register is study-based and it searches the following primary data sources: PubMed, Embase, 8 the Cochrane Central Register of Controlled Trials (CENTRAL), 9 ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), 10 and medRxiv. 11 Retraction Watch is also used to identify retraction notices and expressions of concern. Searches are updated daily in PubMed and ClinicalTrials.gov, weekly in Embase, ICTRP, and medRxiv, and monthly in CENTRAL. The Cochrane COVID-19 Study Register does not search and is not linked to the L·OVE COVID-19 Platform. During our study, the Cochrane registry was negotiating a licensing agreement with Elsevier to publish Embase records in the Cochrane register (i.e., not available for our search). It began searching medRxiv in May 2020 and CENTRAL in November 2020. Given these changes, we conducted a supplemental search on December 29, 2020, to determine whether the missing studies had been added and were available in the registry, by systematically entering in the search field for each missing study: 1) the title, 2) the title and first author's name, 3) the first author's name. We decided to update our database with the studies identified during this process and to present results before and after this update. More details on this process are available in Appendix 1 and at https://community.cochrane.org/about-covid-19-study-register. On September 23, 2020, the L·OVE platform was updated with the addition of observational studies that were available on the L·OVE platform when we exported the data and consequently not screened at the time of our study. We decided to update our database with the observational studies identified during this process and to present results before and after this update. More details on the process are available in Appendix 2 and at https://app.iloveevidence.com/covid19/methods. The reference standard comprised all reports of studies that met the eligibility criteria that were 1) identified during the process of the COVID-NMA initiative, which systematically searched for reports of RCTs, protocols of RCTs and reports of OS from March, 2020, through September 7, 2020 2 (inclusive) or 2) included in two living systematic reviews of RCTs assessing pharmacologic treatment for COVID-19, 12, 13 or 3) identified by any of the two secondary sources evaluated. The search strategy and eligibility criteria of the COVID-NMA initiative and the two living systematic reviews of pharmacologic treatments are detailed here 2 . The searches of the two secondary sources are detailed in Table 1 . They were conducted weekly (each Wednesday at same time) from July 15, 2020 to September 7, 2020 (inclusive). When we conducted the first search (July 15, 2020), records identified in the two secondary sources were downloaded and imported on Rayyan 14 for screening. Updates were screened on MS Excel for the L·OVE platform and on Rayyan for the Cochrane COVID-19 Study Register. All records identified in each secondary source were screened independently by the same two trained reviewers (OP, SC). Disagreements were resolved by consensus and, if necessary, consultation with a senior reviewer. Quality control included systematically checking whether the studies identified in one secondary source were not wrongly excluded during the screening process of the other secondary source. References to all reports meeting our eligibility criteria and identified by the COVID-NMA initiative and in the two living reviews were extracted by two reviewers independently. Any disagreements were resolved by consensus. Our primary outcomes were the proportion of reports included in the reference standard identified by each secondary source. We considered 1) RCT reports, 2) RCT protocols, and 3) OS reportsall assessing interventions for preventing and treating COVID-19. Our secondary outcome was the workload, which we assessed by the total number of records requiring screening when using these two secondary sources. Categorical data were described using percentages, and 95% confidence intervals (CIs). The proportion of studies identified was reported for each type of report (RCTs, RCT protocol, OS) for each platform. We initially planned to evaluate the COVID-Evidence database 15 . However, we only searched the database to August 12, 2020, because the platform was not updated for several weeks and the search strategy had been modified. Consequently, we decided not to report the results. As the L·OVE platform and the Cochrane COVID-19 Study Register were still in process of improvement at the time of the study, we decided to conduct a new search based on the updated platforms. We present both results in the text and the most updated results in the abstract. We informed the responsible parties of both platforms of our results and reported any information that could explain the results. Overall, we identified 680 reports that met our eligibility criteria: 91 RCT reports, 97 RCT protocols, and 492 OS reports (Figure 1 ). After discussing our results with the Cochrane register (R Featherstone), an issue related to the data filter was identified. The filter was working at the study level as opposed to the reference level; the filter retrieved new study records updated in the last week, but it did not retrieve new references added to studies already contained in the register. Consequently, the studies identified after the supplemental search on December 29, 2020 may have been in the registered but not retrieved by the filter. This inconsistency has now been modified. The workload was determined only before the update. We screened 2,645 records from the L·OVE platform and 6,120 from the Cochrane COVID-19 Study Register 5 (Figure 1 ). In contrast, the workload for each living review was more intensive: 45,812 records were The two systematic reviewers also assessed the difficulties of using both secondary sources. The Cochrane COVID-19 Study Register was considered to be the most user-friendly as it allowed filtering by date to identify new studies, a functionality that we did not find on the L·OVE platform at the time of the study. This study assessed the sensitivity of two secondary sources. Our results showed very good sensitivity in the L·OVE COVID-19 platform for all types of reports after the update. It identified all RCTs, RCT protocols, and OS while considerably reducing the workload for this result. Results were also very good for the Cochrane COVID-19 Study Register, which identified 88% of the RCTs, 90% of the RCT protocols, and 82% of the OS after the update. An issue related to the filters implemented in the Cochrane COVID-19 Study Register has been identified and is now corrected. Furthermore, the workload was considerably lower compared to the usual process, particularly on the L·OVE platform. Our results are consistent with other studies evaluating the Cochrane COVID-19 Study Register 3,4,16,17 .To our knowledge, the sensitivity of the L·OVE platform has never been evaluated. Our study has important strengths. The reference standard was based on several sources with high-quality screening processes, and we are confident that we did not miss any reports. Two trained researchers independently performed the search and screening in the two secondary sources, with consensus when they initially disagreed. The screening of the databases was performed independently of the record identified in other sources to avoid verification bias. Our study has important implications. Considering the reduced workload and the high sensitivity of these sources, searching primary sources may be not necessary for systematic reviews assessing COVID-19 interventions, particularly if they are also searching registries. Still, it might be useful to search these two secondary sources as they could serve as a quality control for each other. Our study also has some limitations. We did not include studies evaluating traditional Chinese medicine or other herbal therapies as these interventions were not considered in the COVID-NMA initiative. The platforms evaluated are being continuously improved, and the results may evolve over time. Particularly, the L·OVE COVID-19 platform completed the screening after the end of our study. Similarly, Cochrane was in the process of negotiating their Embase agreement between July and September. Our results showed a considerable improvement of both sources' sensitivity after their updated searches. There may also be an issue related to the time between the moment the study is published and the moment it appears on the different platforms, which might create some delay and decrease our speed in identifying new studies and updating our living systematic review. However, both secondary sources are updated regularly, reducing the likelihood of significant delays. Finally, while we relied on several sources in our reference standard to identify RCTs, the identification of RCT protocols and OS relied only on the COVID-NMA platform and the results identified by the two sources. In conclusion, these secondary sources are essential tools that make living systematic reviews sustainable. The Cochrane COVID-19 Study Register provided very good results, an issue related to the filter has been identified and corrected; a second evaluation will be needed. The L·OVE platform allowed the identification of all studies included in our reference standard and proved to be a viable screening alternative with an acceptable workload. It also implemented some changes (addition of filters) to improve its use. These platforms could be used as a sole source for living evidence synthesis of COVID-19 studies. Weekly update of the search:  we conducted the same searches with a selection of the field -updated‖/ -last week‖. COVID-19) -World Health Organization The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic A search filter to identify pragmatic trials in MEDLINE was highly specific but lacked sensitivity Search strategies to identify observational studies in MEDLINE and Embase Searching ClinicalTrials.gov and the International Clinical Trials Registry Platform to inform systematic reviews: what are the optimal search approaches Living Overview of the Evidence (L·OVE) Cochrane Controlled Register of Trials (CENTRAL) | Cochrane Library Drug treatments for covid-19: living systematic review and network meta-analysis Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) COVID-evidence: a living database of trials on interventions for COVID-19 Evaluation of the comprehensiveness, accuracy and currency of the Cochrane COVID-19 Study Register for supporting rapid evidence synthesis production Machine Learning Reduced Workload for the Cochrane COVID-19 Study Register: Development and Evaluation of the Cochrane COVID-19 Study Classifier /exp OR 'coronavirus infection'/de OR 'SARS-related coronavirus'/de OR 'Severe acute respiratory syndrome coronavirus 2'/exp OR '2019 nCoV':ti,ab,kw OR 2019nCoV:ti,ab,kw OR ((corona* OR corono*) NEAR/1 (virus* OR viral* OR virinae*)):ti,ab,kw OR coronavir*:ti,ab,kw OR coronovir*:ti,ab,kw OR COVID:ti,ab,kw OR COVID19:ti,ab,kw OR HCoV*:ti,ab,kw OR 'nCov 2019':ti,ab,kw OR 'SARS CoV2':ti,ab,kw OR 'SARS CoV 2':ti,ab,kw OR SARSCoV2:ti,ab,kw OR 'SARSCoV 2':ti,ab,kw) NOT (('animal experiment'/de OR 'animal'/exp) NOT ('human'/exp OR 'human experiment'/de))) NOT 'editorial'/it) NOT ([medline]/lim OR COVID-19 OR 2019-nCoV OR SARS-CoV-2 OR coronavirus WHO ICTRP We screen the entire COVID-19 medRxiv We screen the entire COVID-19 results identified by the Stephen B LILACS (Latin American & Caribbean Health Sciences Literature Wanfang Database (updated every 2 weeks) Biomedical Literature Database (updated every 2 weeks) National Knowledge Infrastructure (updated every 2 weeks) Institutional Repository for Information Sharing IRIS PAHO (PAHO Institutional Repository for Information Sharing) Microsoft Academic (last searched ISRCTN registry Chinese Clinical Trial Registry Registry of Clinical Trials NIPH Clinical Trials Search (Japan) -Japan Primary Registries Network (JPRN) (JapicCTI, JMACCT CTR, jRCT, UMIN CTR) Registry of Clinical Trials Republic of Korea (updated daily, via ICTRP search portal) ANZCTR -Australian New Zealand Clinical Trials Registry ReBec -Brazilian Clinical Trials Registry (updated daily, via ICTRP search portal) CTRI -Clinical Trials Registry -India (updated daily, via ICTRP search portal) Public Registry of Clinical Trials (updated daily, via ICTRP search portal) Clinical Trials Registry (updated daily, via ICTRP search portal) Clinical Trials Registry (updated daily, via ICTRP search portal) Netherlands National Trial Register (updated daily, via ICTRP search portal) African Clinical Trial Registry (updated daily, via ICTRP search portal) Clinical Trial Registry (updated daily, via ICTRP search portal) Lanka Clinical Trials Registry (updated daily, via ICTRP search portal) OR "corono virus" OR "virus corono" OR hcov* OR "covid-19" OR covid19* OR "covid 19" OR "2019-ncov" OR cv19* OR "cv-19" OR "cv 19" OR "n-cov" OR ncov* OR (wuhan* and (virus OR viruses OR viral)) OR sars* OR sari OR (covid* and (virus OR viruses OR viral)) OR "severe acute respiratory syndrome" OR mers* OR "middle east respiratory syndrome" OR "middle-east respiratory syndrome" OR "covid-19-related" OR "2019-ncov-related" OR "cv-19-related" OR "n-covrelated" c. Inclusion criteria for the L·OVE database: The database includes all articles related to COVID-19 or other coronaviruses with the following study designs: systematic reviews, primary studies, broad syntheses (e.g., guidelines, overviews of reviews, policy briefs), other articles with designs not included in the above-mentioned categories We are very grateful to Robin Featherstone Information Specialist, Cochrane Editorial & Methods Department and Camila Ávila, Juan Vásquez, Camilo Vergara and Gabriel Rada from Epistemonikos Foundation who provided feedback on our manuscript and facilitated this study. The following search strategy was used coronavir* OR coronovirus* OR betacoronavir* OR "beta-coronavirus" OR "betacoronaviruses" OR "corona virus" OR "virus corona" OR "corono virus" OR "virus corono" OR hcov* OR covid* OR "2019-ncov" OR cv19* OR "cv-19" OR "cv 19" OR "n-cov" OR ncov* OR (wuhan* and (virus OR viruses OR viral)) OR "2019-ncov-related" OR "cv-19related" OR "n-cov-related" OR sars* OR sari OR "severe acute respiratory syndrome" OR antisars* OR "anti-sars-cov-2" OR "anti-sars-cov2" OR "anti-sarscov-2" OR "anti-sarscov-2"